Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tarcocimab · KSI-301, OG-1950

Monoclonal antibody · developed by Kodiak Sciences

Phase 3 Most advanced trial (none active)
KOD Developer
1 Registered trials

What is Tarcocimab?

Tarcocimab tedromer (KSI-301) is an anti-VEGF agent under study for diabetic retinopathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KSI-301, OG-1950
Drug type
Monoclonal antibody
Therapy area
Ophthalmology
Developer
Kodiak Sciences Inc (KOD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
QNU3MX7NBY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06270836 Phase 3 Diabetic Retinopathy Completed KOD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Retinopathy

More from Kodiak Sciences

Follow KOD, the company behind Tarcocimab

See KOD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KOD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.